Alexion Pharmaceuticals shuttered the company’s oral small molecule Factor D inhibitor program for a rare kidney disease following disappointing clinical data.
https://www.pharmalive.com/wp-content/uploads/2020/07/Alexion-Ends-Rare-Kidney-Disease-Program-Following-Poor-Data-BioSpace-7-31-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2020-07-31 12:01:122020-08-04 13:43:47Alexion Ends Rare Kidney Disease Program Following Poor Data